InsiderTradesSIGMA

PicksTOP Companies Executives Performance Blog Topics

InsidersTradesSigma

InsiderTradesSIGMA

Multi-market insider intelligence. Official public filings, re-aggregated and scored. Private beta.

FRUSDEGBCHCAITESNLBENOSEFIDKAUATIEBRINJP+ 8 markets

Recommendations
Companies
Insiders
Performance
Backtest
Compare

Methodology
How it works
Glossary
API docs
Status
Blog

Sign in
Create account
Portfolio
API keys
Alerts
Upgrade

Privacy
Terms
Cookies
Contact
About

Built in Paris. Public sources across 28 markets: AMF France, SEC EDGAR Form 4 US, BaFin Germany, SIX SER Switzerland, RNS United Kingdom, SEDI Canada, Consob Italy, CNMV Spain, AFM Netherlands, FSMA Belgium, Oslo Bors Norway, Nasdaq Helsinki, Nasdaq Copenhagen, ASX Australia, FMA Austria, CVM Brazil, HKEX Hong Kong, BSE-Sofia Bulgaria, Tadawul Saudi Arabia, DART South Korea, EDINET Japan, SSE and SZSE China, SEBI India, KNF Poland, PSE Philippines, NZX New Zealand, JSE South Africa. Prices + fundamentals via Yahoo Finance, STOXX 600 sector ETFs (iShares Xetra). Stack: Next.js 16, Prisma, Vercel. Live out-of-sample tracker since 2026-05-16. Methodology audits: /methodologie and /docs/method-review/.

Sources: official public filings under MAR Art.19 (EU and EEA), SEC Section 16 / Form 4 (US), Art.56 SESTA (CH, SIX SER), NI 55-104 / SEDI (CA), Corporations Act s205G (AU) and equivalent regimes. Signals on this site are for educational use only and do not constitute investment advice within the meaning of MiFID II / SEC Reg-IA. Past performance does not guarantee future results. Swiss SIX SER filings are anonymised by law (role only, no name).

Theme: dark (range regime detected on CAC40 90d · as of 2026-05-22)

© 2026 Insiders TradesΣ·Private beta·Hosted on Vercel

All systems operational

InsidersTradesSigma

AMIT AGGARWAL — reported transactions · 23 reports

← Executives ★ Sign in to follow

AA

AMIT AGGARWAL

ININ·SEBI (PIT + SAST)

Dr. Lal Path Labs Ltd.

Cumul. flow

0

Total declarations

0

Company

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Browse the complete record of transactions filed by AMIT AGGARWAL. Director active across 1 companies, notably Dr. Lal Path Labs Ltd.. In total, 23 filings have been recorded. The latest transaction was disclosed on 4 September 2025 — Sale. Regulator: SEBI (PIT + SAST). All data is accessible without signup.

Declarations23 total

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€18,355550 shares@ €33.3719

Equity Shares

SEBI:00ac299484cf4b6b969835540ed0a28d184eafa2·4 Sept 2025

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€15,092750 shares@ €20.123

Equity Shares

SEBI:8ef3300087bc2371e6d04c37c8e24dfb1850dc5c·19 Sept 2025

Ideal exit: 16 Jun 2026 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€4,888150 shares@ €32.5891

Equity Shares

SEBI:5399ba4e2761d1d03e5146d7a7a246590182d9ed·28 Aug 2025

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€4,981150 shares@ €33.2044

Equity Shares

SEBI:5d032cac5dbf51c045a4e159fc0ab4a83b21aa34·29 Aug 2025

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€4,756250 shares@ €19.0245

Equity Shares

SEBI:858fdf5adb68ced1ae0289567728a3b7fe7cea43·22 Aug 2025

Ideal exit: 19 May 2026 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€9,342275 shares@ €33.9718

Equity Shares

SEBI:832c4ae9aefbafa55d2af31719bafa2346381278·19 Aug 2025

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€86875 shares@ €0.0979

Equity Shares

SEBI:fe8f466acd1d5edeb97341be36bb1cbe464ec973·8 Aug 2025

Ideal exit: 5 May 2026 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€17,737500 shares@ €35.4736

Equity Shares

SEBI:4d2e12f233475d3549cafd6afe2b10a7c47eddc4·23 Sept 2024

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€10,347500 shares@ €20.694

Equity Shares

SEBI:4b1a9c3758024b26b93e5769afc534fb658646b5·17 Sept 2024

Ideal exit: 14 Jun 2025 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€18,424500 shares@ €36.8485

Equity Shares

SEBI:61dfeaf42db4fd0042e3e62aff760d4f673f28ee·12 Sept 2024

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€18,421500 shares@ €36.8415

Equity Shares

SEBI:d806254d92f24cd28c9261a04c618bde6b793252·10 Sept 2024

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€14,490400 shares@ €36.2249

Equity Shares

SEBI:71bd1c8576dc1072a710917028174844e9329a72·28 Aug 2024

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€22,0381,000 shares@ €22.0376

Equity Shares

SEBI:030185f55dd94170820edf29372baec51a4cb9c8·4 Sept 2024

Ideal exit: 1 Jun 2025 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€14,693400 shares@ €36.7313

Equity Shares

SEBI:a2d484e070cf7a4a6ab278be598a6ea82dd7bc64·30 Aug 2024

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€14,310400 shares@ €35.7741

Equity Shares

SEBI:3f88ac10b5eaf3815c3cec596e5f4a05b58cd01f·20 Aug 2024

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€35,4391,000 shares@ €35.4387

Equity Shares

SEBI:c092ef2d6730b6935be5af1349afdf4f98b9a20c·16 Aug 2024

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€7,138200 shares@ €35.6914

Equity Shares

SEBI:c6329bf519b850431adb7bc5cd9d904d69b11780·13 Aug 2024

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€2382,200 shares@ €0.1083

Equity Shares

SEBI:11f9995b8116946e02633e288c9464ee576a269f·13 Aug 2024

Ideal exit: 10 May 2025 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€30,5921,000 shares@ €30.5919

Equity Shares

SEBI:198e551f2c35e2d6b5b09423dbd434fe56cdd429·13 Jun 2024

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€18,007600 shares@ €30.0118

Equity Shares

SEBI:d7587c94100c6cd323f7800a6c291ea38c26bd38·31 May 2024

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€12,169400 shares@ €30.422

Equity Shares

SEBI:8818390549daab48c2d39b224cff31e94c8120a9·7 Nov 2023

Executives●PurchaseDDr. Lal Path Labs Ltd.0SEBI

A

€80700 shares@ €0.115

Equity Shares

SEBI:20480614b346599ca565d28d3cfac519b8ec441e·6 Jan 2023

Ideal exit: 3 Oct 2023 (T+270)

Executives●SaleDDr. Lal Path Labs Ltd.0SEBI

A

€15,290475 shares@ €32.1903

Equity Shares

SEBI:c76e5763b26520072b7c916070648c20fb298b8d·26 Sept 2022

23 of 23 declarations